Monday, October 21, 2013

DDP TV: Andy Donnelly, MEDIMMUNE

The demand for new drug delivery technologies continues to increase, but the drug delivery process can still be very risky. So what are some of the key considerations for the delivery innovation funnel? Andy Donnelly, Associate Director, Drug Delivery and Device Development, Formulation Sciences, MEDIMMUNE, discusses the identification process of new drug delivery technologies, as well as the impact of Pharma's shift from small molecules to biologics.

What are some other key elements to consider when developing new drug delivery technologies?

IIR's 18th Annual Drug Delivery Partnerships will help you form a drug delivery strategy that keeps you ahead of the market, register today! As a reader of this blog you'll receive 15% off of the standard rate when you use priority code XP1978BLOG to register. To learn more, download our agenda. We hope to see you January 27-29 in Boca Raton!

No comments:

Post a Comment